Topical glucocorticosteroids: efficacy and safety in gynecology
- Authors: Zyryanov S.K1,2, Butranova O.I1
-
Affiliations:
- Peoples' Friendship University of Russia
- City Clinical Hospital No. 24, Moscow City Health Department
- Issue: No 5 (2021)
- Pages: 166-173
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/249280
- DOI: https://doi.org/10.18565/aig.2021.5.166-172
- ID: 249280
Cite item
Abstract
Full Text
About the authors
S. K Zyryanov
Peoples' Friendship University of Russia; City Clinical Hospital No. 24, Moscow City Health Department
Email: zyryanovsk@rudn.university
M.D, professor, the Head of the Department of General and Clinical Pharmacology of the Medical Institute, Peoples' Friendship University of Russia; Deputy Chief Medical Officer, City Clinical Hospital No. 24, Moscow City Health Department. 117198, Russia, Moscow, Miklukho-Maklaya str., 6; 127015, Russia, Miscow, Pistzovaya str., 10
O. I Butranova
Peoples' Friendship University of Russia
Email: butranova-oi@rudn.ru
Ph.D, Associated Professor of the Department of General and Clinical Pharmacology of the Medical Institute 117198, Russia, Moscow, Miklukho-Maklaya str., 6
References
- Das A., Panda S. Use of topical corticosteroids in dermatology: An evidence-based approach. Indian J. Dermatol. 2017; 62(3): 237-50. https://dx.doi. org/10.4103/ijd.IJD_169_17.
- Goldstein A. T., Marinoff S. C., Christopher K., Srodon M. Prevalence of vulvar lichen sclerosus in a general gynecology practice. J. Reprod. Med. 2005; 50(7): 477-80.
- Egan M.E., Lipsky M.S. Diagnosis of vaginitis. Am. Fam. Physician. 2000; 62(5): 1095-104.
- Paladine H.L., Desai U.A. Vaginitis: diagnosis and treatment. Am. Fam. Physician. 2018; 97(5): 321-9.
- Brander E.P.A., McQuillan S.K. Prepubertal vulvovaginitis. CMAJ. 2018; 190(26): E800. https://dx.doi.org/10.1503/cmaj.180004.
- Aballea S., Guelfucci F., Wagner J., Khemiri A., Dietz J.P., Sobel J., Toumi M. Subjective health status and health-related quality of life among women with Recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA. Health Qual. Life Outcomes. 2013; 11: 169. https://dx.doi.org/10.1186/1477-7525-11-169.
- Oakley R.H., Cidlowski J.A. The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease. J. Allergy Clin. Immunol. 2013; 132(5): 1033-44. https://dx.doi.org/10.1016/j.jaci.2013.09.007.
- Ramamoorthy S., Cidlowski J.A. Corticosteroids: mechanisms of action in health and disease. Rheum. Dis. Clin. North Am. 2016; 42(1): 15-vii. https:// dx.doi.org/10.1016/j.rdc.2015.08.002.
- Samarasinghe R.A., Witchell S.F., DeFranco D.B. Cooperativity and complementarity: synergies in non-classical and classical glucocorticoid signaling. Cell Cycle. 2012; 11(15): 2819-27. https://dx.doi.org/10.4161/ cc.21018.
- Vandewalle J., Luypaert A., De Bosscher K., Libert C. Therapeutic mechanisms of glucocorticoids. Trends Endocrinol. Metab. 2018; 29(1): 42-54. https://dx.doi. org/10.1016/j.tem.2017.10.010.
- Panettieri R.A., Schaafsma D., Amrani Y., Koziol-White C., Ostrom R., Tliba O. Non-genomic effects of glucocorticoids: An updated view. Trends Pharmacol. Sci. 2019; 40(1): 38-49. https://dx.doi.org/10.1016/j.tips.2018.11.002.
- Chung Y.S., Jin H.L., Jeong K.W. Cell-specific expression of ENACa gene by FOXA1 in the glucocorticoid receptor pathway. Int. J. Immunopathol. Pharmacol. 2020; 34: 2058738420946192. https://dx.doi.org/10.1177/2058738420946192.
- Vitellius G., Trabado S., Bouligand J., Delemer B., Lombes M. Pathophysiology of glucocorticoid signaling. Ann. Endocrinol. (Paris). 2018; 79(3): 98-106. https:// dx.doi.org/10.1016/j.ando.2018.03.001.
- Sainte Marie Y., Toulon A., Paus R., Maubec E., Cherfa A., Grossin M. et al. Targeted skin overexpression of the mineralocorticoid receptor in mice causes epidermal atrophy, premature skin barrier formation, eye abnormalities, and alopecia. Am. J. Pathol. 2007; 171(3): 846-60. https://dx.doi.org/10.2353/ ajpath.2007.060991.
- Uva L., Miguel D., Pinheiro C., Antunes J., Cruz D., Ferreira J., Filipe P. Mechanisms of action of topical corticosteroids in psoriasis. Int. J. Endocrinol. 2012; 2012: 561018. https://dx.doi.org/10.1155/2012/561018.
- Niculet E., Bobeica C., Tatu A.L. Glucocorticoid-induced skin atrophy: The old and the new. Clin. Cosmet. Investig. Dermatol. 2020; 13: 1041-50. https:// dx.doi.org/10.2147/CCID.S224211.
- Galon J., Franchimont D., Hiroi N., Frey G., Boettner A., Ehrhart-Bornstein M. et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J. 2002; 16(1): 61-71. https:// dx.doi.org/10.1096/fj.01-0245com.
- Radoja N, Komine M., Jho S.H., Blumenberg M., Tomic-Canic M. Novel mechanism of steroid action in skin through glucocorticoid receptor monomers. Mol. Cell. Biol. 2000; 20(12): 4328-39. https://dx.doi.org/10.1128/ mcb.20.12.4328-4339.2000.
- Kosztyu P, Hill M., Jemelkova J., Czernekova L., Kafkova L.R., Hruby M. et al. Glucocorticoids reduce aberrant O-glycosylation of IgA1 in IgA nephropathy patients. Kidney Blood Press. Res. 2018; 43(2): 350-9. https://dx.doi. org/10.1159/000487903.
- Johnson E., Groben P, Eanes A., Iyer P, Ugoeke J., Zolnoun D. Vulvar skin atrophy induced by topical glucocorticoids. J. Midwifery Womens Health. 2012; 57(3): 296-9. https://dx.doi.org/10.1111/j.1542-2011.2012.00189.x.
- Renaud-Vilmer C., Cavelier-Balloy B., Porcher R., Dubertret L. Vulvar lichen sclerosus: effect of long-term topical application of a potent steroid on the course of the disease. Arch. Dermatol. 2004; 140(6): 709-12. https:// dx.doi.org/10.1001/archderm.140.6.709.
- Coondoo A., Phiske M., Verma S., Lahiri K. Side-effects of topical steroids: A long overdue revisit. Indian Dermatol. Online J. 2014; 5(4): 416-25. https:// dx.doi.org/10.4103/2229-5178.142483.
- Gual A., Pau-Charles I., Abeck D. Topical corticosteroids in dermatology: From chemical development to galenic innovation and therapeutic trends. J. Clin. Exp. Dermatol. Res. 2015; 6: 269. https://dx.doi.org/10.4172/2155-9554.1000269.
- Cross S.E., Magnusson B.M., Winckle G., Anissimov Y., Roberts M.S. Determination of the effect of lipophilicity on the in vitro permeability and tissue reservoir characteristics of topically applied solutes in human skin layers. J. Invest. Dermatol. 2003; 120(5): 759-64. https://dx.doi.org/10.1046/ j.1523-1747.2003.12131.x.
- Pellanda C., Strub C., Figueiredo V., Rufli T., Imanidis G., Surber C. Topical bioavailability of triamcinolone acetonide: effect of occlusion. Skin Pharmacol. Physiol. 2007; 20(1): 50-6. https://dx.doi.org/10.1159/000096172.
- Haque T., Talukder M.M.U. Chemical enhancer: A simplistic way to modulate barrier function of the stratum corneum. Adv. Pharm. Bull. 2018; 8(2): 169-79. https://dx.doi.org/10.15171/apb.2018.021.
- Kapoor M.S., Guha Sarkar S., Banerjee R. Stratum corneum modulation by chemical enhancers and lipid nanostructures: implications for transdermal drug delivery. Ther. Deliv. 2017; 8(8): 701-18. https://dx.doi.org/10.4155/ tde-2017-0045.
- Farage M., Maibach H.I. The vulvar epithelium differs from the skin: implications for cutaneous testing to address topical vulvar exposures. Contact Dermatitis. 2004; 51(4): 201-9. https://dx.doi.org/10.1111/j.0105-1873.2004.00444.x.
- Connor C.J., Eppsteiner E.E. Vulvar contact dermatitis. Proc. Obstet. Gynecol. 2014; 4(2): Article 1. https://dx.doi.org/10.17077/ 2154-4751.1255.
- Rathi S.K., D'Souza P. Rational and ethical use of topical corticosteroids based on safety and efficacy. Indian J. Dermatol. 2012; 57(4): 251-9. https:// dx.doi.org/10.4103/0019-5154.97655.
- Nicolaides N.C., Pavlaki A.N., Maria Alexandra M.A., Chrousos G.P. Glucocorticoid therapy and adrenal suppression. Updated 2018 Oct 19. In: Feingold K.R., Anawalt B., Boyce A., Chrousos G., de Herder W.W., Dhatariya K., eds. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. Available at: https://www.ncbi.nlm.nih.gov/books/NBK279156/
- Burger-Stritt S., Bachmann L., Kurlbaum M., Hahner S. Emergency treatment of adrenal crisis with prednisone suppositories: a bioequivalence study in female patients with Addison's disease. Endocr. Connect. 2019; 8(4): 425-34. https:// dx.doi.org/10.1530/EC-19-0024.
- Tromm A., Mollmann H., Barth J., Hochhaus G., Krieg M., Bigalke C., Mollmann A, Derendorf H. Pharmacokinetics and rectal bioavailability of hydrocortisone acetate after single and multiple administration in healthy subjects and patients. J. Clin. Pharmacol. 2001; 41(5): 536-41. https://dx.doi. org/10.1177/00912700122010410.
- Mollmann H., Barth J., Mollmann C., Tunn S., Krieg M., Derendorf H. Pharmacokinetics and rectal bioavailability of hydrocortisone acetate. J. Pharm. Sci. 1991; 80(9): 835-6. https://dx.doi.ois/10.1002/jps.2600800906.
- Van der Meijden W.I., Boffa M.J., Ter Harmsel W.A., Kirtschig G., Lewis F.M., Moyal-Barracco M., Tiplica G.S., Sherrard J. 2016 European guideline for the management of vulval conditions. J. Eur. Acad. Dermatol. Venereol. 2017; 31(6): 925-41. https://dx.doi.org/10.1111/jdv.14096.
- Anderson M., Kutzner S., Kaufman R.H. Treatment of vulvovaginal lichen planus with vaginal hydrocortisone suppositories. Obstet. Gynecol. 2002; 100(2): 35962. https://dx.doi.org/10.1016/s0029-7844(02)02117-8.
- Fischer G. Treatment of vaginitis and vulvitis. Aust. Prescr. 2001; 24(3): 59-61. https:/dx./doi.org/10.18773/austprescr.2001.067.
- Woelber L., Prieske K., Mendling W., Schmalfeldt B., Tietz H.J., Jaeger A. Vulvar pruritus-causes, diagnosis and therapeutic approach. Dtsch. Arztebl. Int. 2020; 116(8): 126-33. https://dx.doi.org/10.3238/arztebl.2020.0126.
- Sheppard C. Treatment of vulvovaginitis. Aust. Prescr. 2020; 43(6): 195-9. https://dx.doi.org/10.18773/austprescr.2020.055.
- Lambert J. Pruritus in female patients. Biomed. Res. Int. 2014; 2014: 541867. https://dx.doi.org/10.1155/2014/541867.
- Chi C.C., Wang S.H., Wojnarowska F., Kirtschig G., Davies E., Bennett C. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst. Rev. 2015; (10): CD007346. https://dx.doi.org/10.1002/14651858.CD007346.pub3
- Аполихина И.А., Саидова А.С., Куликов И.А., Баранов И.И. Применение нового комбинированного препарата для местного применения (метронидазол + хлорамфеникол + натамицин + гидрокортизона ацетат) для лечения вагинитов различной этиологии. Акушерство и гинекология. 2020; 7: 143-50.